Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A ...Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P?P?P?P?P?P?展开更多
目的探讨经尿道绿激光前列腺汽化术(photoselective vaporization of the prostate,PVP)、经尿道前列腺等离子剜除术(transurethra plasma kinetic enucleation of the prostate,PKEP)、经尿道前列腺等离子双极电切术(transurethra plas...目的探讨经尿道绿激光前列腺汽化术(photoselective vaporization of the prostate,PVP)、经尿道前列腺等离子剜除术(transurethra plasma kinetic enucleation of the prostate,PKEP)、经尿道前列腺等离子双极电切术(transurethra plasma kinetic resection of the prostate,PKRP)在高龄高危前列腺增生症(benign prostatic hyperplasia,BPH)患者中的应用价值。方法240例高龄高危BPH患者被随机分为A、B、C组,每组各80例。A、B、C组分别采用PVP、PKEP和PKRP进行治疗。比较3组患者的围手术期指标、应激反应指标、炎症因子浓度、并发症、国际前列腺症状评分、生活质量评分、最大尿流率和残余尿量。结果在手术时间、术中失血量、留置尿管时间、膀胱冲洗时间、术后住院时间方面,A组最优,B组次之,C组最差(P<0.05)。术后1 d的Cor、NE、E、FBG、IL-6、IL-2、IL-1β、TNF-α浓度以A组最低,B组次之,C组最高(P<0.05)。A组的短暂性尿失禁发生率明显低于B组(P<0.0125)。结论在围手术期指标、应激反应和全身炎症反应方面,PVP最优,PKEP次之,PKRP最差,但3中术式的近期效果无差别,其中PKEP的短暂性尿失禁发生率较高。展开更多
目的探讨经尿道前列腺等离子电切术(Transurethral plasma kinetic resection of prostate,PKRP)治疗前列腺增生的临床效果。方法选择2019年1月至2020年1月于本院进行手术治疗的前列腺增生患者113例,分为对照组56例和观察组57例。对照...目的探讨经尿道前列腺等离子电切术(Transurethral plasma kinetic resection of prostate,PKRP)治疗前列腺增生的临床效果。方法选择2019年1月至2020年1月于本院进行手术治疗的前列腺增生患者113例,分为对照组56例和观察组57例。对照组采用经尿道前列腺电切术(Transurethral resection of prostate,TURP)治疗,观察组采用经尿道前列腺等离子电切术治疗。对比两组患者围术期各项指标,手术前后实验室指标、尿路功能指标和并发症发生情况。结果观察组手术时间、术中出血量、膀胱冲洗时间、导尿管拔除时间和住院时间均低于对照组(P<0.05);观察组出院时,实验室指标血前列腺特异性抗原(PSA)、血小板衍生生长因子BB(PDGF-BB)和单核细胞趋化因子-1(MCP-1)水平,膀胱残余尿量(RU)、国际前列腺症状评分(IPSS)和生活质量评分(QoL)及并发症发生率均低于对照组,最大尿流率(Qmax)高于对照组,差异有统计学意义(P<0.05)。结论PKRP可有效缩短前列腺增生患者手术时间、膀胱冲洗时间等围术期指标,改善PSA等实验室指标和尿路功能,降低并发症发生率,安全性较好。展开更多
文摘Objective: To evaluate the efficacy and safety of terazosin and plasma kinetic resection of the prostate (PKRP) in the treatment of benign prostatic hyperplasia (BPH) patients with coexisting hypertension. Methods: A total of 205 men who suffered from BPH with concomitant hypertension were enrolled in this study. They all received PKRP surgery and terazosin medication from one week before to 3 months after the operation. The procedures of efficacy and safety were evaluated by analysis of the changes in blood pressures, IPSS, Qmax and the drug related adverse events 4 weeks and 3 months after the operation. Results: The systolic blood pressure decreased from 161 ± 12.33 mmHg at baseline to 148 ± 7.27 mmHg four weeks (P?P?P?P?P?P?
文摘目的探讨经尿道绿激光前列腺汽化术(photoselective vaporization of the prostate,PVP)、经尿道前列腺等离子剜除术(transurethra plasma kinetic enucleation of the prostate,PKEP)、经尿道前列腺等离子双极电切术(transurethra plasma kinetic resection of the prostate,PKRP)在高龄高危前列腺增生症(benign prostatic hyperplasia,BPH)患者中的应用价值。方法240例高龄高危BPH患者被随机分为A、B、C组,每组各80例。A、B、C组分别采用PVP、PKEP和PKRP进行治疗。比较3组患者的围手术期指标、应激反应指标、炎症因子浓度、并发症、国际前列腺症状评分、生活质量评分、最大尿流率和残余尿量。结果在手术时间、术中失血量、留置尿管时间、膀胱冲洗时间、术后住院时间方面,A组最优,B组次之,C组最差(P<0.05)。术后1 d的Cor、NE、E、FBG、IL-6、IL-2、IL-1β、TNF-α浓度以A组最低,B组次之,C组最高(P<0.05)。A组的短暂性尿失禁发生率明显低于B组(P<0.0125)。结论在围手术期指标、应激反应和全身炎症反应方面,PVP最优,PKEP次之,PKRP最差,但3中术式的近期效果无差别,其中PKEP的短暂性尿失禁发生率较高。
文摘目的探讨经尿道前列腺等离子电切术(Transurethral plasma kinetic resection of prostate,PKRP)治疗前列腺增生的临床效果。方法选择2019年1月至2020年1月于本院进行手术治疗的前列腺增生患者113例,分为对照组56例和观察组57例。对照组采用经尿道前列腺电切术(Transurethral resection of prostate,TURP)治疗,观察组采用经尿道前列腺等离子电切术治疗。对比两组患者围术期各项指标,手术前后实验室指标、尿路功能指标和并发症发生情况。结果观察组手术时间、术中出血量、膀胱冲洗时间、导尿管拔除时间和住院时间均低于对照组(P<0.05);观察组出院时,实验室指标血前列腺特异性抗原(PSA)、血小板衍生生长因子BB(PDGF-BB)和单核细胞趋化因子-1(MCP-1)水平,膀胱残余尿量(RU)、国际前列腺症状评分(IPSS)和生活质量评分(QoL)及并发症发生率均低于对照组,最大尿流率(Qmax)高于对照组,差异有统计学意义(P<0.05)。结论PKRP可有效缩短前列腺增生患者手术时间、膀胱冲洗时间等围术期指标,改善PSA等实验室指标和尿路功能,降低并发症发生率,安全性较好。